Glucosamine and Alzheimer's: what a popular joint supplement may mean for the brain

Glucosamine is a supplement that millions of people around the world take for joint pain and osteoarthritis. Sold over the counter, it is marketed as one of the amino sugars that build cartilage. A new analysis reported by Science Daily, however, raises a signal that glucosamine use may speed up the progression of Alzheimer's disease in patients who have already been diagnosed with dementia.

The study's basic logic is this: researchers reviewed long-term follow-up records of existing dementia patients and compared groups who regularly took glucosamine with those who did not. The rate of decline on cognitive tests, hippocampal atrophy on imaging and worsening of daily living activity scores were faster in the users than in the non-users.

What could the mechanism be? Scientists are looking at three possible explanations. First, glucosamine may alter insulin signalling and shift brain glucose metabolism — already impaired in Alzheimer's. Second, it may produce mild fluctuations in blood sugar. Third, it may exert an indirect neurological effect through changes in the gut microbiome. None of these is yet certain.

What the findings mean for whom matters. The study shows the strongest signal in people previously diagnosed with dementia; the same signal was not significantly observed in cognitively healthy adults. So for someone taking glucosamine for joint pain who is cognitively healthy, the study does not deliver a direct warning sign; but for diagnosed dementia patients, the concern is clear.

The literature on glucosamine's established benefits is itself debated. Cochrane reviews suggest that glucosamine sulphate produces a small reduction in pain compared with placebo in mild-to-moderate osteoarthritis, while evidence for glucosamine hydrochloride is weak. Some clinicians say that, given new risk signals around a supplement whose clinical benefit is small, use may need to be re-evaluated.

In practice, medical advice is essential. If an individual diagnosed with dementia is taking glucosamine, the decision to stop should be evaluated first by their neurologist and primary-care doctor, because in some patients glucosamine may have meaningfully reduced osteoarthritis pain, and stopping it could cause a separate loss in daily-living activities. The overall risk-benefit assessment is individual.

The global glucosamine market was worth about 1.2 billion US dollars in 2023; in many countries, including Türkiye, it is available over the counter. Because of this, the new findings carry the weight of a public-health-level signal that must be considered. Whether the European Medicines Agency will issue an opinion on the topic or whether the Cochrane reviews will be updated is worth following.

For general users, Science Daily's recommendation is transparency rather than panic. If you take glucosamine for joint pain and have no dementia diagnosis or suspected diagnosis, the current study does not deliver a direct danger signal. If you are a diagnosed dementia patient, or have a first-degree relative with early-onset Alzheimer's, it makes sense to discuss the issue with your healthcare provider.

The study restates the evidence on lifestyle factors that protect against Alzheimer's disease. Regular aerobic exercise, a Mediterranean-style diet, sleep hygiene, social interaction, correction of hearing loss, control of hypertension and diabetes, and lifelong learning with cognitive challenge. Stopping glucosamine does not replace any of these fundamental protective measures.

The practical take-away for Vesper readers can be summarised in three points. First, the study found no signal of increased dementia risk from glucosamine in healthy adults. Second, patients with a dementia diagnosis or a first-degree family history should not continue the supplement without speaking to their doctor. Third, the long-term plan for joint pain rests on a much stronger foundation built on physiotherapy, weight management, strength training and, when appropriate, discussion of pain medication — not on supplementation alone.